Downstream and into deep biology: Evolving business models in 'top tier' genomics companies
Genomics companies are changing their business models and some have moved beyond drug discovery into drug development. The authors' analysis of genomics companies' business models yields further insights into the widening role of genomics firms within drug innovation and on the evolving dynamics between the genomics sector and the wider pharmaceutical industry. Business models within the sector have included that of the FIPCO (Fully Integrated Pharmaceutical Company), technology and information platforms, and, more recently, a new 'dual' business model that combines established platform capabilities with drug development. The study identifies a cohort of 22 leading genomics companies and takes as its focus those companies following the dual and platform business strategies. The paper describes how, over the past five years, leading genomics companies have, typically, refocused their interests downstream within drug innovation, a move that brings new commercial opportunities but also threats. New and evolving business models are enabling these companies to leverage their commercial positions and capture value in the later stages of drug development. These shifts are characterised and the possibility that this 'downstream' trend could exert a major effect on the future relations between genomics companies and pharma/large biotechnology firms, and on drug innovation, is explored.
유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.
- 이 논문과 함께 출판된 논문 + 더보기